期刊
CURRENT MOLECULAR MEDICINE
卷 7, 期 4, 页码 417-425出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156652407780831601
关键词
-
资金
- NIAMS NIH HHS [R01 AR050202, R01 AR049722, R01 AR050202-02, R01 AR049722-02, AR050202, AR049722] Funding Source: Medline
A number of forms of congenital muscular dystrophy (CMD) have been identified that involve defects in the glycosylation of dystroglycan with O-mannosyl-linked glycans. There are at least six genes that can affect this type of glycosylation, and defects in these genes give rise to disorders that have many aspects of muscle and brain pathology in common. Overexpression of one gene implicated in CMD, LARGE, was recently shown to increase dystroglycan glycosylation and restore its function in cells taken from CMD patients. Overexpression of Galgt2, a glycosyltransferase not implicated in CMD, also alters dystroglycan glycosylation and inhibits muscular dystrophy in a mouse model of Duchenne muscular dystrophy. These findings suggest that a common approach to therapy in muscular dystrophies may be to increase the glycosylation of dystroglycan with particular glycan structures.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据